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Purpose: Hypoxia-inducible factor-1 (HIF-1) is a key transcription factor that regulates the cellular adaptation to hypoxia.
HIF-1α gene single nucleotide polymorphisms (SNPs) are implicated to be associated with cancer risks. However, results
from the published studies remained inconclusive. The aim of this study is to investigate the relationship of HIF-1α gene
G1790A polymorphism with cancer using meta-analysis.
Methods: A comprehensive search in Pubmed, EMBASE and China National Knowledge Infrastructure (CNKI) was
conducted to identify all publications on the association between this polymorphism and cancer until December 13,
2013. Odds ratios (OR) with 95% confidence intervals (95% CI) were used to evaluate the strength of this association.
Association between lymph node metastasis and G1790A was also investigated.
Results: A total of 5985 cases and 6809 controls in 28 case–control studies were included in this meta-analysis.
The A allele of HIF-1α gene G1790A polymorphism was found to be significantly associated with increased
cancer risk in four genetic models: AA + AG vs. GG (dominant model OR = 1.85, 95% CI = 1.27-2.69), AA vs. AG +
GG (recessive model OR = 5.69, 95% CI = 3.87-8.37), AA vs. GG (homozygote comparison OR = 6.63, 95% CI = 4.49-9.79),
and AG vs. GG (heterozygote comparison OR = 2.39, 95% CI = 1.53-3.75). This variant was also significantly associated
with higher risks of pancreatic cancer, head and neck cancer, lung cancer and renal cell carcinoma. However, the A
allele of G1790A was not significantly associated with increased lymph node metastasis in the dominant model by
overall meta-analysis.
Conclusions: Our meta-analysis suggests that the substitution of G with A of HIF-1α gene G1790A polymorphism is a
risk factor of cancer, especially for pancreatic cancer, lung cancer, renal cell carcinoma and head and neck cancer. The
association is significant in Asian, Caucasian population and public based control subgroups. However, it’s not associated
with risk of lymph node metastasis.
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Cancer is a multifactorial disease involving interac-
tions between inherited and environmental factors [1].
Hypoxia is one of the fundamentally important charac-
teristics of solid cancer [2]. It triggers a cascade of mo-
lecular events including angiogenesis and involving
cell-cycle control proteins, which are closely associ-
ated with tumor growth, metastasis and poor progno-
sis. These responses to hypoxia are highly dependent
on the activation of hypoxia inducible factor-1-alpha
(HIF-1α).
Hypoxia-inducible factor-1 (HIF-1) is a key transcrip-
tion factor that regulates the cellular adaptation to hyp-
oxia. HIF-1 trans-activates a large number of genes that
are involved in cellular processes, such as glucose uptake
and metabolism, angiogenesis, cell proliferation, differ-
entiation and apoptosis [3,4]. HIF-1 is a heterodimeric
transcription factor that consists of α and β subunits. Β
subunit is constitutively expressed while the expession of
HIF-1α is regulated by the oxygen level [5]. Under nor-
moxic conditions, HIF-1α is degraded due to targeted
ubiquitination and degradation by the proteasome. This
process is mediated by direct binding of von Hippel–
Lindau tumor suppressor protein (pVHL), a component
of the E3 ubiquitin–protein ligase complex, with the
minimal N-terminal transactivation domain (N-TAD),
which is located within the oxygen-dependent degrad-
ation domain of HIF-1α. On the contrary, in hypoxic
conditions, the degradation of HIF-1α is suppressed
and the expression of HIF-1α increases in the cell.
Over-expression of HIF-1α has been reported in many
types of cancer, including lung, prostate, breast, colon
and rectum carcinoma, and in regional or distant me-
tastases, implying that it may play a vital role in tumor
progression [6-11].
A number of polymorphisms and mutations have been
identified within HIF-1α gene, among them, G1790A
(rs11549467), which results in alanine to threonine amino
acid substitutions has been found recently. It is located
within the oxygen-dependent degradation domain of the
HIF-1α gene. This polymorphic variant has been shown to
cause an increased trans-activation capacity of HIF-1α
under hypoxic conditions in vitro [12]. The possible asso-
ciation between HIF-1α SNPs and cancer risk has been
studied by several investigators, but the results were in-
conclusive or even contradictory [7,9,11,13-20]. Tongfeng
Zhao et al. [21] conducted a meta-analysis about HIF-1α
polymorphisms and cancer risk in 2009, however, the
sample size was limited (2058 cancer cases and 3062 con-
trols) and studies published in the past 3 years were not
included. In order to obtain a more comprehensive know-
ledge of the association between HIF-1α G1790A poly-
morphism and cancer risk, a meta-analysis on eligible
case–control studies was conducted.Method
Literature search and data extraction
A comprehensive literature search in PubMed, Embase
and China National Knowledge Infrastructure (CNKI)
database was carried out by two reviewers independently
to identify publications evaluating the association of can-
cer risk and HIF-1α G1790A polymorphism (last update:
December 13, 2013). The search terms used were as
follows: (cancer or carcinoma) and (Hypoxia-inducible
factor-1α or HIF-1α) and (Polymorphism or mutation
or variant). Selection criteria of an eligible study were:
(a) investigation of the polymorphism G1790A of HIF-
1α and cancer risk; (b) use of a case–control design
based on unrelated individuals and (c) sufficient geno-
type distributions for cases and controls so that an
odds ratio (OR) with 95% confidence interval (CI) could
be estimated. If more than one article was published using
the same patient population, only the latest or the study
with largest sample size would be used in this meta-analysis.
Data including publication date, first author, original
country, ethnicity, gender and cancer site (those cancer
sites only exist in one article were divided into “other
site group”), total number of casea and controla, source
of control (population-based or hospital-based) and
genotyping method were independently extracted by
two investigators and conformity on all items was reached
through consultation. Articles containing data on lymph
node metastasis were also extracted. Patients were divided
into “lymph node metastasis positive” group and “lymph
node metastasis negative” group [8-10,16,22-24].
Statistical study
Crude odds ratios (ORs) and 95% confidence intervals
(95% CIs) were used to estimate the strength of associ-
ation between the G1790A and cancer risk or lymph
node metastasis and they were determined by Z-test.
The pooled ORs were estimated for the genetic models
including dominant model (AA + AG vs. GG), recessive
model (AA vs. AG +GG), homozygote comparison (AA
vs. GG) and heterozygote comparison (AG vs. GG). The
models were selected based on the following assumptions:
1. Dominant model: The heterozygous (AG) and
homozygous (AA) genotypes have similar risk as a
single copy of A is sufficient to alter the risk. Hence
these two genotypes are combined and compared
with the homozygous GG.
2. Recessive model: The AG and GG genotypes have
the same effect. Hence to modify two copies of A
allele is essential. Therefore this model compares the
combination of AG +GG with the homozygous
genotype variant allele AA.
3. Homozygote/Heterozygote comparison: Ignoring the
effect of heterozygotes/homozygotes.
Figure 1 Flow chart of the process of selecting related publications.
Table 1 Characteristics of populations and cancer types of the studies included in the meta-analysis
Author Year Country Ethnicity Cancer site Case–control Gendera Soure of control Genotyping method HWE
Ribeiro AL 2013 Portugal Caucasian Breast cancer 96/74 Female HB PCR-RFLP 0.00
Alves LR 2012 Brazil Brazilian Head and neck cancer 88/40 Mixed PB PCR-RFLP 0.69
Li P 2012 China Asian Prostate cancer 662/716 Male PB TaqMan 0.55
Mera-Menendez F 2012 Spain Caucasian Head and neck cancer 121/154 Mixed PB PCR–RFLP 0.69
Ruiz-Tovar J 2012 Spain Caucasian Pancreatic cancer 59/159 Mixed PB PCR-RFLP 0.68
Kuo WH 2012 China Asian Lung cancer 285/300 Mixed PB PCR–RFLP 0.15
Qin C 2012 China Asian Renal cell carcinoma 620/623 Mixed PB PCR-RFLP 0.42
Wang X 2011 China Asian Pancreatic cancer 263/271 Mixed PB PCR-RFLP 0.49
Putra AC 2011 Japan Asian Lung cancer 83/110 Mixed PB PCR 0.65
Kim YH 2011 Korea Asian Other cancer 199/215 Female PB PCR-RFLP 0.14
Shieh TM 2010 China Asian Head and neck cancer 305/96 Mixed PB PCR-RFLP 0.71
Hsiao PC 2010 China Asian Other cancer 102/347 Mixed HB PCR-RFLP 0.70
Chen MK 2009 China Asian Head and neck cancer 174/347 Mixed PB PCR-RFLP 0.70
Naidu R 2009 Malaysia Asian Breast cancer 410/275 Female PB PCR-RFLP 0.90
Konac E 2009 Turkey Caucasian Lung cancer 141/156 Mixed HB PCR-RFLP 0.94
Li K 2009 China Asian Other cancer 87/106 Mixed PB PCR 0.76
Munoz-Guerra MF 2009 Spain Caucasian Head and neck cancer 74/139 Mixed PB PCR-RFLP 0.69
Kim HO 2008 Korea Asian Breast cancer 90/102 Female PB PCR 0.06
Apaydin I 2008 Turkey Caucasian Breast cancer 102/102 Female PB PCR-RFLP 0.84
Li H 2007 USA Mixed Prostate cancer 1072/1271 Male PB PCR-RFLP 0.81
Orr-Urtreger A 2007 Israel Caucasian Prostate cancer 402/300 Male PB PCR-RFLP 0.95
Fransen K 2006 Sweden Caucasian Other cancer 198/258 Mixed PB PCR-RFLP 0.77
Konac E-Ob 2007 Turkey Caucasian Other cancer 49/107 Female PB PCR-RFLP 0.00
Konac E-Cc 2007 Turkey Caucasian Other cancer 32/107 Female PB PCR-RFLP 0.00
Konac E-Ed 2007 Turkey Caucasian Other cancer 21/107 Female PB PCR-RFLP 0.00
Ollerenshaw M 2004 UK Caucasian Renal cell carcinoma 160/288 Mixed PB PCR-RFLP 0.00
Tanimoto K 2003 Japan Asian Head and neck cancer 55/110 Mixed PB PCR-RFLP 0.65
Clifford SC 2001 UK Caucasian Renal cell carcinoma 35/143 Mixed HB PCR-RFLP 0.00
aMixed means samples contain both female and male; PB, public based; HB, hospital based; HWE, Hardy-Weinberg equilibrium; PCR, polymerase chain reaction;
RFLP, restriction fragment length polymorphism; TaqMan, TaqMan SNP Genotyping Assays.
bcdThe article of Konac E provided data on three kinds of cancers (cervical cancer, endometrial cancer and ovarian cancer), Konac E-O stands for ovarian cancer;
Konac E-C stands for cervical cancer; Konac E-E stands for endometrial cancer.
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Figure 2 A allele frequency of HIF-1α G1790A among control
subjects stratified by ethnicity.
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was considered statistically significant. As most articles
only used (AA +AG vs. GG) model for lymph node ana-
lysis, only this genetic model (AA +AG vs.GG) was used
in the lymph node metastasis analysis.Table 2 Associations between the G1790A polymorphism and
Varibles AA + AG VS GG AA VS AG +
na OR (95% CI) Pb na OR (95% CI
Overall 25 1.85 (1.27-2.69 ) 0 26 5.69 (3.87-8.37
Overall for HWEc 22 1.82 (1.27-2.59) 0 10 7.01 (4.42-11.0
cancer cite
Prostate cancer 3 1.41 (0.93-2.14) 0.1 1 3.24 (0.13-79.9
Head and neck cancer 6 3.57 (0.98-12.99) 0.05 3 58 (1.75-1924.8
Pancreatic cancer 2 2.5 ( 0.93-6.72) 0.06 1 18.8 (0.96-371.5
Lung cancer 3 2.14 ( 1.56-2.95) 0 2 4.5 (2.3-8.81)
Renal cell carcinoma 3 0.94 ( 0.16-5.29) 0.95 2 2.69 (1.20-6.03
Other cancer 5 2.11 ( 1.03-4.32) 0.45 1 0.35 (0.01-8.80
Breast cancer 3 0.63 ( 0.19-2.08) 0 2 1.44 (0.34-6.08
Subgroup by ethnicity
Asian 13 1.75 (1.3-2.37) 0 7 3.37 (1.94-5.86
Caucasian 9 1.12 (0.41-3.03) 0.81 4 3.74 (1.85-7.54
control source
PB 22 1.95 (1.33-2.85) 0 11 5.9 (4.0-8.8)
HB 3 0.39 (0.01-9.90) 0.56 1 0.88 (0.04-16.82
Gender
Female 5 0.92 (0.46-1.84) 0.82 3 1.11 (0.34-3.66
Male 3 1.41 (0.93-2.14) 0.1 1 3.24 (0.13-79.9
aNumber of comparisons.
bP value of Q-test for heterogeneity test.
cData after excluding those studies’ controls not in Hardy-Weinberg equilibrium.In addition to the comparison between cases and con-
trols, subgroup analyses were also performed according
to cancer site, ethnicity, source of controls and gender.
Heterogeneity was evaluated by a chi square-based
Q statistic, and statistical significance was assumed for
P value less than 0.05. A fixed-effect model was used
when P heterogeneity was more than 0.05, otherwise a
random effect model was used. Sensitivity analysis was
performed to assess the stability of the current analysis.
Studies which didn’t follow Hardy–Weinberg equilibrium
(HWE) were excluded [25].
Publication bias was examined visually by the Begg’s
funnel plot and the degree of asymmetry was tested by
Egger’s test.
All of the statistical tests were performed by STATA11.0.
Results
Characteristics of studies included
Basic characteristics of studies
463 relevant publications were identified after initial screen-
ing based on our search criteria (last updated on December
13, 2013). After reading the titles and abstracts, 47 articles
were subjected to further examination. 18 articles were ex-
cluded for no relevance to G1790A. 3 articles were excluded
as allele frequency was not reported (Figure 1). Finally, acancer risk
GG AA VS GG AG VS GG
) Pb na OR (95% CI) Pb na OR (95% CI) Pb
) 0 12 6.63 (4.49-9.79) 0 11 2.39 (1.53-3.75) 0
9) 0 10 7.75 (4.87-12.34) 0 10 3.4 (2–5.8) 0
) 0.47 1 3.34 (0.13-82.30) 0.46 1 1.98 (0.07-50.4) 0.67
8) 0.02 3 101.38 (22.09-65.29) 0 3 12.53 (2.42-64.76) 0
5) 0.05 1 18.3 (0.93-360.19) 0.05 1 29.4 (1.12-772.37) 0.04
0 2 5.42 (2.74-10.7) 0 2 3.02 (1.48-6.16) 0
) 0.01 2 3.71 (1.72-7.99) 0.46 1 0.81 (0.33-2) 0.65
) 0.53 1 0.35 (0.01-8.8) 0.52 1 0.36 (0.01-9.68) 0.54
) 0.62 2 1.43 (0.37-5.44) 0.59 2 1.45 (0.34-6.17) 0.61
) 0 7 3.82 (2.19-6.66) 0 7 2.41 (1.31-4.43) 0
) 0 4 5.05 (2.53-10.07) 0 3 2.66 (0.33-21.23) 0.35
0 11 7.2 (4.79-10.82) 0 11 2.39 (1.53-3.75) 0
) c 0.93 1 0.44 (0.02-8.53) 0.59 0 No statistics
) 0.85 3 1.13 (0.34-3.7) 0.83 3 1.13 (0.31-4.02) 0.84
) 0.47 1 3.34 (0.13-82.3) 0.46 1 1.98 (0.07-50.4) 0.67
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with 5985 cases and 6809 controls in total were included in
the pooled analysis. Out of those 28 studies, 6 studies fo-
cused on head and neck cancer, 3 on prostate cancer, 4 on
breast cancer, 3 on lung cancer, 3 on renal cell carcin-
oma, 2 on pancreatic cancer and 7 on other types of
cancers such as gastric, hepatocellular and colorectal
cancer. Among the 26 articles, 1 article provided data
on three types of cancer (cervical cancer, endometrial
cancer and ovarian cancer) [7]. Each type of cancer in
one article was treated as an individual study in the
meta-analysis. The ethnicities studied included Cauca-
sian (13 articles), Asian (13 articles), Brazilian (1 art-
icle) and mixed population (1 article). The gender
studied were female (8 articles), male (17 articles) and
mixed (3 articles). 7 articles provided data on lymph
node metastasis, 1511 negative cases and 491 positive
cases were included.
Characteristics of allele average frequency
In the control group, no significant difference of the
average A allele frequency of HIF-1α G1790A was de-
tected between Asian population (0.040) and Caucasian
population (0.045) (P = 0.7, t-test) (Figure 2).Figure 3 Forest plot of cancer risk associated with G1790A (AA + AG
respectively. The area of the squares indicates the study-specific weight.Quantitative data synthesis
G1790A polymorphisms and cancer: a meta-analysis of 28
case–control studies
Aggregated ORs and heterogeneity test results for the as-
sociation between G1790A and cancer risk were shown in
Table 2. The forest plots of cancer risk associated with
G1790A (AA +AG vs. GG) were shown in Figures 3, 4, 5,
6 and 7.
Overall, A allele of G1790A was found to be significantly
associated with increased cancer risk in four genetic models:
AA+AG vs. GG (dominant model OR= 1.85, 95% CI =
1.27-2.69), AA vs. AG+GG (recessive model OR= 5.69,
95% CI = 3.87-8.37), AA vs. GG (homozygote comparison
OR= 6.63, 95% CI = 4.49-9.79), and AG vs. GG (heterozy-
gote comparison OR= 2.39, 95% CI = 1.53 -3.75).
In cancer-site subgroup analysis, significant association
with cancer risk was found in the following genetic
models: AA vs.AG in pancreatic cancer (OR = 29.4, 95%
CI = 1.12-772.37); AA +AG vs. GG (OR = 2.14, 95% CI =
1.56-2.95), AA vs. GG+AG (OR= 4.5, 95% CI = 2.3-8.81)
and AA vs. GG (OR = 5.42, 95% CI = 2.74-10.7) in lung
cancer; AA vs. GG+AG (OR = 58, 95% CI = 1.75-
1924.88), AA vs. GG (OR = 101.38, 95% CI = 22.09-65.29 )
and AG vs. GG (OR = 12.53, 95% CI = 2.42-64.76) in headVS GG). The squares and horizontal lines represent OR and 95% CI,
Figure 4 Forest plot of cancer risk associated with G1790A (AA + AG VS GG) stratified by cancer site.
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1.2 -6.03) and AA vs.GG (OR = 3.71, 95% CI = 1.72-7.99)
in renal cell carcinoma.
As for ethnicity subgroup analysis, significant associ-
ation was detected in Asian population in all four
genetic models: AA + AG vs. GG (OR = 1.75, 95% CI =
1.3-2.37), AA vs. AG +GG (OR = 3.37, 95% CI = 1.94-
5.86), AA vs. GG (OR = 3.82, 95% CI = 2.19-6.66), and
AG vs. GG (OR = 2.41, 95% CI = 1.31-4.43). However, in
Caucasian subgroup, significant increased risk was only
found in the following models: AA vs. GG + AG (OR =
3.74, 95% CI = 1.85-7.54) and AA vs. GG (OR = 5.05,
95% CI = 2.53-10.07).
When stratified by control sources, significant associ-
ation was found among public based control source in
these models: AA + AG vs. GG (OR = 1.91, 95% CI = 1.3-
2.8), AA vs. AG + GG (OR = 5.9, 95% CI = 3.97-8.75), AA
vs. GG (OR = 7.2, 95% CI = 4.79-10.82), and AG vs. GG
(OR = 2.39, 95% CI = 1.53-3.7). However, no significant as-
sociation was found among hospital based control source.G1790A polymorphisms and lymph node metastasis: a
meta-analysis of 7 case–control studies
As for lymph node metastasis analysis, no significant
association between A allele of G1790A and increased
lymph node metastasis was found for AA + AG vs.GG
(OR = 1.56, 95% CI = 0.99-2.46).
When stratified by ethnicity and control source, sig-
nificant higher risk of lymph node metastasis was found
in Caucasian (OR = 14.28, 95% CI = 1.74-117.17), Asian
(OR = 1.39, 95% CI = 1.01-1.92) and public based popula-
tion (OR = 1.62, 95% CI = 1.01-2.61) for AA + AG vs.GG
(Table 3).
Heterogeneity analysis and sensitivity analysis
Significant heterogeneity was found in overall compari-
sons in four genetic models: dominant model P < 0.01,
recessive model P < 0.01, homozygote comparison P < 0.01
and heterozygote comparison P < 0.05. Although the geno-
type distribution in the control group of 6 studies did not
follow HWE, the pooled ORs only altered a little after we
Figure 5 Forest plot of cancer risk associated with G1790A (AA + AG VS GG) stratified by ethnicity.
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didn’t change (Table 2).
Publication bias
The shape of the funnel plots did not reveal any evi-
dence of obvious asymmetry (Figure 8), suggesting that
there was no obvious publication bias. Egger’s test
showed no significant publication bias in this meta-
analysis (t = 0.77, P = 0.45 for AA + AG vs. GG).
Discussion
HIF-1 is a key transcription factor that regulates cellular
reaction to hypoxia and is over-expressed in most solid
tumors in response to low oxygen concentrations [12]. It
has the ability to influence metabolic reprogramming,
angiogenesis, metastasis and over-expression of HIF-1α
has been reported in many types of cancers as well as in
regional or distant metastatic lesions [22,26].
Several polymorphisms in HIF-1 gene have been sug-
gested to be related with individual’s predisposition to
cancer [7,27,28]. Among them, G1790A has been re-
cently identified [27]. The possible association betweenG1790A and cancer risk has been extensively studied,
but the results are inconclusive. One possible reason is
that the rareness of A allele in both case and control
populations [29] allows only a small number of A car-
riers to be analyzed in many studies. In order to get a
more precise conclusion, a comprehensive meta-analysis
including 28 case–control studies was performed.
In the current study, we summarized the latest data on
the association between G1790A of HIF-1α gene poly-
morphism and cancer risk. Subgroup analysis by cancer
site, ethnicity, source of controls and gender were also
performed, based on four genetic models.
Overall meta-analysis showed that the A allele of
G1790A was significantly associated with increased can-
cer risk in all four genetic models. One possible mechan-
ism is that G1790A SNP results in amino acid change
from alanine 588 to threonine within the Oxygen
dependent degradation (ODD) domain of the HIF-1α
gene. Such amino acid change in this critical regulatory
domain may enhance the transcriptional activity of HIF-
1α gene [12]. It may also increase the stability of HIF-1α
protein and promote the binding ability of HIF-1α
Figure 6 Forest plot of cancer risk associated with G1790A (AA + AG VS GG) stratified by source of control subjects.
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sion of downstream target genes. The protein products of
these target genes play crucial roles in the acute and
chronic adaptation of cells to oxygen deficiency, including
erythropoiesis, glycolysis, promotion of cell survival, in-
hibition of apoptosis, inhibition of cell differentiation and
angiogenesis, all of which are critical in tumor formation,
invasion and metastasis [27]. Further studies are required
to address this question.
When stratified by cancer site, significant association be-
tween A allele of G1790A and increased cancer risk was
observed in pancreatic cancer, lung cancer, renal cell car-
cinoma and head and neck cancer, but not in breast cancer,
prostate cancer and other cancers. As cancer of different
sites are exposed to different micro-environmental factors
that can regulate or influence the gene expression profiles,
gene-environment interaction may be different in these
cancers. Furthermore, different tissues have different ex-
pression profiles of HIF-1α, thus the same polymorphism
may play different role in different tissues [30,31]. However,
all those results should be treated with caution as there
were only 2 or 3 studies included in some cancer site sub-
groups, which might reduce the results’ reliability.
As for subgroup of ethnicity, despite the possible gen-
etic background difference among different ethnicities[32], as well as environment and life-style difference be-
tween Asian and Caucasian, A allele of G1790A was
found to be significantly associated with increased can-
cer risk in both Asian and Caucasian population. How-
ever, population of this subgroup analysis was limited to
Caucasian and Asian only. No study based on African
participants found. Further case–control studies with
large sample size and multiple ethnicities are required.
It has been reported that HIF-1α may facilitate lymph
node metastasis by reducing cell adhesion, degrading
extracellular matrix through up-regulating matrix metal-
loproteinase (MMPs) or lysyl oxydase (LOX) [33] and
increasing chemotaxis [3,34]. As G1790A enhances the
stability and trans-activating capacity of HIF-1α [12], it
is possible that it may also affect the risk of lymph node
metastasis. In the current study, the association between
A allele carriers (AA or AG) and the risk of lymph node
metastasis in 7 case–control studies was not observed.
After stratification by ethnicity and control source, sig-
nificant association of AA or AG genotype with risk of
lymph node metastasis was found in Caucasian and
Asian, and PB population. However, only 1 or 2 studies
were available for each subgroup analysis and only the
dominant model (AA + AG vs. GG) was used. Therefore,
the results should be treated with caution.
Figure 7 Forest plot of cancer risk associated with G1790A (AA + AG VS GG) stratified by gender.
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four genetic models in both overall and subgroup ana-
lysis. Six studies included in our meta-analysis did not
follow HWE. Deviation from HWE reflects potential er-
rors existing in those 6 studies, such as laboratory or
genotyping errors, population stratification or selection
bias in the choice of controls and unaccounted con-
founding factors [25,35]. Sensitivity analysis was per-
formed to assess the stability of the current analysis.
After excluding those 6 studies deviated from HWE, the
conclusions didn’t change, indicating that our conclu-
sions were stable.Table 3 Associations between the G1790A polymorphism
and lymph node metastasis risk
Varibles na AA + AG VS GG
OR (95% CI) Pb
Overall 7 1.56 (0.99-2.46) 0.05
PB 6 1.62 (1.01-2.61) 0
Asian 6 1.39 (1.01-1.92) 0.04
Caucasian 1 14.28 (1.74-117.17) 0.01
aNumber of comparisons.
bP value of Q-test for heterogeneity test.There were still some limitations in the current meta-
analysis. The sample size for some subgroup analysis
was limited, which could increase the possibility of type
I and type II errors. Even though our funnel plot and
Egger’s test did not show any bias, publication bias was
also not avoidable, as positive results have higherFigure 8 Funnel Plot of publication bias of the G1790A
Polymorphism. Each point represents a single study for the
indicated association. Log (OR): natural logarithm of OR. Horizontal
line: mean effect size.
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on Asian and Caucasian population, and no studies
were from Africans. Thus, further studies are needed
in other ethnic population because of possible ethnic
differences of G1790A polymorphism.
Conclusions
Our meta-analysis suggests that the substitution of G al-
lele with A of HIF-1α gene G1790A polymorphism is a
risk factor of cancer, especially for pancreatic cancer,
lung cancer, renal cell carcinoma and head and neck
cancer. The association is significant in Asian, Caucasion
population and public based control subgroups. How-
ever, it’s not associated with risk of lymph node metasta-
sis by overall meta-analysis. When stratified by ethnicity
and control source, significant higher risk of lymph node
metastasis was found in Caucasian, Asian and public
based population.
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